Urology Conferences

First-line Pazopanib May Improve Outcomes in Advanced RCC

First-line Pazopanib May Improve Outcomes in Advanced RCC

By

Treatment-naïve patients with advanced clear-cell renal cell carcinoma had significantly longer progression-free survival when treated with pazopanib instead of temsirolimus.

Upfront Docetaxel May Have Role in Advanced Prostate Cancer

Upfront Docetaxel May Have Role in Advanced Prostate Cancer

By

Added to hormone therapy, docetaxel offers a cost effective way to prolong hormone-sensitive disease and improve quality of life years, especially among men with non-metastatic disease, study finds.

Non-urothelial Bladder Cancer Type Affects Disease-Specific Survival

Non-urothelial Bladder Cancer Type Affects Disease-Specific Survival

By

Patients with bladder adenocarcinomas have the best survival, whereas those with small cell carcinomas of the bladder have the worst.

Metastatic RCC Treatment With Nivolumab Confirmed Safe, Efficacious

Metastatic RCC Treatment With Nivolumab Confirmed Safe, Efficacious

By

The safety and efficacy of nivolumab for treating metastatic renal cell carcinoma is comparable to that found in the CheckMate 025 trial.

Axitinib-Pembrolizumab Combo Promising for Advanced RCC

Axitinib-Pembrolizumab Combo Promising for Advanced RCC

By

In a phase Ib study, dual therapy with axitinib and pembrolizumab was well tolerated and demonstrated antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.

Cytoreductive Nephrectomy May Up Survival in Papillary mRCC

Cytoreductive Nephrectomy May Up Survival in Papillary mRCC

By

Study reveals a 38% decreased risk of death in patients with papillary metastatic renal cell carcinoma who undergo cytoreductive nephrectomy vs those who do not.

Metastatic Kidney Cancer Outcomes Improved With Combined Therapy

Metastatic Kidney Cancer Outcomes Improved With Combined Therapy

By

Immunotherapy with atezolizumab plus targeted therapy with bevacizumab improves progression-free survival better than sunitinib in patients with untreated metastatic renal cell carcinoma.

Low-Carb Diet Tested as Way to Slow Recurrent Prostate Cancer

Low-Carb Diet Tested as Way to Slow Recurrent Prostate Cancer

By

In a small phase 2 study of overweight men with recurrent prostate cancer, consuming less than 20 grams of carbohydrates a day resulted in profound weight loss.

PSA Trajectory in nmCRPC Predicts Metastasis, Mortality Risk

PSA Trajectory in nmCRPC Predicts Metastasis, Mortality Risk

By

Metastasis and death are more likely to occur among patients with relatively high PSA levels at diagnosis of nmCRPC and rising PSA levels during follow-up.

Adverse Prostate Cancer Pathology Accurately Predicted With MRI

Adverse Prostate Cancer Pathology Accurately Predicted With MRI

By

Multiparametric MRI has high positive and negative predictive values for extracapsular extension, seminal vesicle invasion, lymph node involvement, and high-risk Gleason score.

Urologic Cancer Surgery Readmission Rate Highest for RC

Urologic Cancer Surgery Readmission Rate Highest for RC

By

In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.

Early Prostate Cancer Salvage ADT Therapy Better

Early Prostate Cancer Salvage ADT Therapy Better

By

Among men who had PSA failure following radiation therapy for localized PCa, those with a long PSA doubling time had an increased risk of PCa mortality if they started androgen-deprivation therapy later.

Prostate Cancer Pathologic Features Worse in Blacks

Prostate Cancer Pathologic Features Worse in Blacks

By

Black men undergoing radical prostatectomy for prostate cancer are more likely to have indications for adjuvant radiotherapy compared with white men.

Statin Use May Improve Survival in Advanced Prostate Cancer

Statin Use May Improve Survival in Advanced Prostate Cancer

By

Statin use is associated with greater overall survival among men with metastatic castration-resistant prostate cancer and improved survival among patients with high-risk prostate cancer.

Negative Repeat Biopsy in PCa Active Surveillance a Positive Sign

Negative Repeat Biopsy in PCa Active Surveillance a Positive Sign

By

In a study, a negative confirmatory prostate biopsy in prostate cancer patients on active surveillance predicts a lower risk of progressing to treatment.

Earlier Prostate Cancer Drug Use in CRPC Cuts Metastasis Risk

Earlier Prostate Cancer Drug Use in CRPC Cuts Metastasis Risk

By

In separate studies, apalutamide and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.

Testosterone Therapy May Reduce PCa Risk in Hypogonadal Men

Testosterone Therapy May Reduce PCa Risk in Hypogonadal Men

By

In a study of hypogonadal men, those who received testosterone therapy had a lower incidence of prostate cancer than those who did not.

Low-PSA, High-Grade Prostate Cancer Especially Lethal

Low-PSA, High-Grade Prostate Cancer Especially Lethal

By

Men with PSA values of 2.5 ng/mL or less and Gleason 8 to 10 prostate tumors are at higher risk of death than other high-risk PCa patients.

Worse Survival After Robotic Cystectomy Seen at Low-Volume Centers

Worse Survival After Robotic Cystectomy Seen at Low-Volume Centers

By

The researchers found lower overall survival among patients undergoing robot-assisted radical cystectomy at hospitals performing 10 or fewer procedures during 2010 to 2012.

MRI Accuracy for Prostate Cancer Challenged

MRI Accuracy for Prostate Cancer Challenged

By

Systematic biopsies always should be performed in conjunction with targeted biopsy in men with suspected clinically significant PCa at mpMRI.

Novel PSA Assay Improves Prostate Cancer Diagnosis

Novel PSA Assay Improves Prostate Cancer Diagnosis

By

The new test, IsoPSA, measures all PSA isoforms in serum and more accurately discriminates high-grade cancer from benign disease.

Pure Bladder Cancer Variants Linked to Worse Survival After RC

Pure Bladder Cancer Variants Linked to Worse Survival After RC

By

Patients with a pure variant had significantly lower survival odds than those with pure urothelial carcinoma over a median 6.5 years of follow up.

Real-World mUCB Patient Survival Worse Than in Clinical Trials

Real-World mUCB Patient Survival Worse Than in Clinical Trials

By

Just 1 in 4 patients diagnosed with metastatic urothelial carcinoma of the bladder survive for a year, according to US national registry data.

Robot-assisted Radical Cystectomy on the Rise

Robot-assisted Radical Cystectomy on the Rise

By

By 2014 to 2015, 1 in 3 bladder cancer surgical procedures performed in the United States were robot-assisted.

Neoadjuvant Chemo Benefits Some Variant MIBC Patients

Neoadjuvant Chemo Benefits Some Variant MIBC Patients

By

Researchers find prolonged survival among patients with neuroendocrine muscle-invasive bladder cancer.

Post-chemo PD-L1 Tied to Worse Prognosis in Bladder Cancer Pts

Post-chemo PD-L1 Tied to Worse Prognosis in Bladder Cancer Pts

By

Five-year cancer-specific survival rates were 48.1% and 69.6% for PD-L1 positive and negative patients, respectively.

AUA Releases Updated Renal Mass Guidelines

AUA Releases Updated Renal Mass Guidelines

By

The document spells out in greater detail the criteria for radical and partial nephrectomy and for placing patients on active surveillance.

Imaging Technique Improves Bladder Tumor Surveillance

By

Daneshmand: Blue flexible cystoscopy used in an office-setting can improve detection of bladder cancer recurrence.

PCa Active Surveillance Safe, Effective for Younger Patients

PCa Active Surveillance Safe, Effective for Younger Patients

By

A majority of active surveillance patients under age 60 did not progress to definitive prostate cancer treatment.

MRI-Fusion Biopsy Benefits PCa Active Surveillance Patients

MRI-Fusion Biopsy Benefits PCa Active Surveillance Patients

By

Targeting PI-RADS 4 and 5 lesions for confirmatory biopsy improves detection of clinically significant cancer.

Sign Up for Free e-newsletters